CING News and Press, Cingulate Inc. From 12/27/23

2023-12-27 12:23:36 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Cingulate Inc (NASDAQ...

2023-12-27 10:00:36 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...

2023-12-27 09:57:20 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Opthea Ltd (NASDAQ: OPT), Ci...

2023-12-27 08:27:59 ET First Wave BioPharma FWBI +107% on plans to sell niclosamide program . Cingulate ( CING ) +89% . Cytokinetics CYTK +53% on positive Phase 3 data for heart disease therapy . Jet.AI ( JTAI ) +38% . Cohe...

2023-12-18 08:26:30 ET Losers: Chanson International Holding ( CHSN ) -88% . Inno Holdings ( INHD ) -85% . Maison Solutions ( MSS ) -84% issues statement regarding short attack on its securities . Aadi Bioscience ( AADI ) -56% . Sing...

2023-12-15 10:00:27 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Myomo, Aileron...

KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products,...

2023-11-14 09:19:40 ET More on Cingulate Seeking Alpha’s Quant Rating on Cingulate Historical earnings data for Cingulate Financial information for Cingulate For further details see: Cingulate GAAP EPS of -$0.30 misses by $0.02

Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company), a biopharmaceut...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...